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MDL 17,043, an agent with both inotropic and vasodi-
lator properties, was evaluated in the treatment of chronic
severe heart failure. The early and late hemodynamic,
hormonal, pharmacokinftic and clinical responses to oral
MDL 17,043 were studied in 20 patients. MDL 17,043
acutely increased cardiac output from 3.6 ± 0.9 to
4.6 ± 1.0 liters/min (+28%, P < 0.001) and decreased
mean pulmonary artery wedge pressure from 24 ± 8 to
13 ± 8 mm Hg (-46%, P < 0.001), mean right atrial
pressure from 10 ± 5 to 4 ± 4 mm Hg (-60%, P <
0.001) and mean arterial pressure from 78 ± 9 to 70 ±
11 mm Hg (-10%, P < 0.001). Hemodynamic improve-
ment was sustained for 8 hours. Plasma renin activity
tended to increase (0.10 < P > 0.05), plasma norepi-
nephrine tended to decrease (0.10 < P > 0.05) and ar-
ginine vasopressin did not show any directional change.
Elimination halt-life for MDL 17,043 was llpproximately
20 hours.
Inotropic therapy attempts to counteract directly the con-
tractile deficit in myocardial failure. Such theoretic appeal
has led to the development of several potential agents for
the treatment of heart failure (1-3). One such compound is
MOL 17,043 (4). This drug possesses vasodilating as well
as inotropic properties (5). The exact mechanism for these
actions has not been defined, although this agent is known
to be a potent phosphodiesterase inhibitor (6). In previous
studies from our laboratory (4,7), we have shown intrave-
nous and oral MOL 17,043 to produce a dramatic short-
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Hemodynamic responsiveness was maintained in six
patients undergoing restudy at 4 weeks. Initial subjective
improvement in the 20 patients occurred in 90%, was
present at 4 weeks in 50% and continued longer than 3
months in 25%. Side effects occurred in 75% and re-
quired cessation of treatment in 10%. Thirteen (93%)
of 14 patients on long-term therapy died (median time
after start of MDL 17,043 therapy 39 days). Deaths were
sudden in 69%.
It is concluded that oral MDL 17,043 produces early
and late hemodynamic improvement in patients with
severe heart failure. The clinical response suggests cau-
tion in its use and controlled trials to ascertain whether
MDL 17,043 is safe and efficacious in chronic severe
heart failure.
(J Am Coil CardioI1985;5:1414-21)
term improvement in hemodynamic status. The long-term
hemodynamic effects of this agent, however, have not been
clarified and the short- and long-term hormonal response
and pharmacokinetics have not been described. To evaluate
the utility of MOL 17,043 in the treatment of chronic heart
failure, we investigated the early and late hemodynamic,
hormonal, pharmacokinetic and clinical responses to this
agent in patients with severe heart failure.
Methods
Patients. Twenty patients with severe heart failure were
studied, after giving informed consent, using a protocol
approved by our institution's Human Use Committee. The
origin of the heart failure was ischemic in 11, idiopathic in
7 and hypertensive in 1; 1 patient with long-standing mitral
regurgitation and severe myocardial dysfunction despite a
well functioning valve prosthesis was studied. There were
16 men and 4 women. Fifteen were in New York Heart
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Association functional class IV and 5 were in class III. The
average age was 61 ± 12 years. The average ejection frac-
tion by radionuclide or contrast angiography was 16 ± 5%,
blood urea nitrogen was 35 ± 24 mg/100 ml and creatinine
was 1.7 ± 0.8 mg/lOO ml.
The following vasodilators had previously been used by
the referring physician and considered by the referring phy-
sician to be not totally satisfactory: a nitrate preparation in
13, captopril in 11, hydralazine in 5 and prazosin in 4. All
vasodilator drugs were withheld for at least 18 hours before
invasive study. Short-term intravenous dobutamine in two
patients and dopamine in one patient had previously been
infused. All patients were receiving diuretic and digitalis
therapy. These agents were withheld the day of the invasive
study.
Study ProtocoL
Early study. In the initial hemodynamic study right heart
pressures and cardiac output were measured through a triple
lumen Swan-Ganz thermodilution catheter. Femoral artery
pressure was measured directly. Cardiac output was deter-
mined in triplicate (with less than 10% variation) using iced
5% dextrose solution. Oxygen saturation and hemoglobin
were measured from the systemic and pulmonary artery
blood to determine systemic arteriovenous oxygen difference.
Supine baseline measurements at rest of pressures, car-
diac output and systemic arteriovenous oxygen difference
were obtained in duplicate 15 minutes apart. Baseline data
represent an average of these values. Patients were then
given a single dose of oral MDL 17,043 (the first 10 patients
received 3 mg/kg and the second 10 patients 6 mg/kg).
Hemodynamic measurements were made at 30 minutes and
1 to 8 hours after drug administration. The initial dose of
3 mg/kg was chosen on the basis of an intravenous study
from our laboratory (4) suggesting that 3 mg/kg is in the
middle of the dose-response curve.
Blood samples for plasma norepinephrine, renin activity
and arginine vasopressin were obtained after the second set
of baseline hemodynamic measurements, which were at least
1 hour after the patient was in the supine position. Blood
for hormone levels were obtained at 1 and 4 hours after
MDL 17,043 administration. Plasma norepinephrine was
measured using high performance liquid chromatography
(8). Plasma renin activity and arginine vasopressin were
measured using previously described radioimmunoassay
techniques (9,10). Hormone levels were obtained during
early and late invasive studies in all patients.
Blood was obtained at baseline, coincident with each
hemodynamic measurement, and at 24 hours after drug
administration (18 patients) to measure plasma levels of
MDL 17,043 and a major hemodynamically active metab-
olite MDL 19,438 (l,3-dihydro-4-methyl-5-[4-methylsul-
finyl]-benzoyl-2H-imidazol-2-one) (7) using a high per-
formance liquidchromatography method (11). The elimination
half-life (TI/2) was estimated by fitting a simple linear
regression to the terminal decay phase of the 10gIO plasma
concentrations. The elimination rate (h- I ) is then: k, =
2.303 b, where b is the estimated slope of the linear regres-
sion. The elimination half-life (h) is TV2 = 0.693/ke. Four-
teen of the 20 patients had both relatively normal renal
function (creatinine < 2.0 mg/lOO ml) and sufficient data
to calculate TV2 for the early study.
An electrocardiogram and the following laboratory data
were obtained before and on the day after invasive testing:
complete blood count with differential, platelet count, uri-
nalysis and determinations of alkaline phosphatase, serum
glutamic oxaloacetic transaminase, serum glutamic pyruvate
transaminase, bilirubin, blood urea nitrogen, creatinine,
glucose, cholesterol, sodium, potassium, chloride, bicar-
bonate, calcium, phosphorus, uric acid, albumin and total
protein.
Derived hemodynamic variables including systemic vas-
cular and pulmonary arteriolar resistance and stroke work
index were calculated using standard formulas (4).
Late study. After completion of the initial hemody-
namic study, patients were offered long-term use of the
agent. All agreed to continue taking the agent and to be
seen weekly as an outpatient for the first 4 weeks and monthly
thereafter or daily in the hospital. At these visits, the patient
was questioned specifically regarding cardiovascular symp-
toms and signs, overall status and side effects. An electro-
cardiogram and blood studies as listed were measured. Re-
sponses were entered on standardized data forms. For
analytical purposes, patients were given an overall score of
"improved," "unchanged" or "worsened" in relation to
baseline at each evaluation point. Death was considered
sudden if it was witnessed and occurred within 1 hour of
the onset of symptoms, usually with an abrupt loss of con-
sciousness, or if it was unwitnessed and occurred within 24
hours of the time the patient was last seen in his usual
state of health. Patients were allowed to continue on all
medications, including vasodilators, if it was believed that
clinical improvement, albeit incomplete, had occurred as a
result of these medications.
All 20 patients agreed to return for a second hemody-
namic study at 4 weeks; 6 patients actually underwent this
study. The reasons for not undergoing a second hemody-
namic evaluation included the following: death before 4
weeks of oral MDL 17,043 treatment (six), hospitalization
at an outside institution and subsequent death (one), wors-
ened state requiring changes in medication including use of
dobutamine (two), side effects from MDL 17,043 resulting
in cessation of drug use before 4 weeks (one), patient refusal
(one), patient dropped from study by investigator because
of poor compliance (one) and patient dropped from study
by referring physician (one). One patient was admitted for
restudy feeling subjectively improved over baseline but de-
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Results
Hemodynamic response. Improvement in most mea-
sured and calculated hemodynamic variables was apparent
by 30 minutes after administration of MOL 17,043 , and by
2 hours improvement was evident in all variables (Table I).
The hemodynamic measurements for the group of patients
given 3 rug/kg and those given 6 mg/kg were not signifi-
cantly different either at baseline or at any time after MDL
17,043 administration.
The six patients who underwent the 4 week study (Table
2) demonstrated baseline late hemodynamic measurements
similar to those of the entire group in the early study, except
for a small but significant increase in heart rate at rest in
the late compared with the early study. These six patients
felt subjectively improved . The peak early and late hemo-
dynamic responses were nearly identical.
Hormonal response. Plasma norepinephrine and renin
activity were not changed significantly at I hour after oral
MOL 17,043 administration (Table 3). Plasma renin activity
tended to increase at 4 hours (0.1 < P > 0.05, baseline
versus 4 hours), whereas norepinephrine levels tended to
decrease at 4 hours (0.1 < P > 0.05) . Plasma arginine
vasopressin did not show any significantdirectional changes.
Baseline plasma norepinephrine (763 ± 329 pg/ml), renin
activity (14.2 ± 14.4 ng/ml per h) and arginine vasopressin
(1.8 ± 0.9 pg/ml) levels were similar at restudy in the six
patients as compared with the early study (early baseline
plasma norepinephrine 968 ± 461 [pg/ml]; plasma renin
activity 14.3 ± 14.4 [ng/ml per h] and arginine vasopressin
veloped a supraventricular tachycardia at a rate of greater
than 200 beats/min and the study was postponed. Shortly
after discharge, the patient had symptoms of digitoxicity
and the serum digoxin level was elevated. Hospitalization
for this problem was advised, but the patient refused and
died suddenly the same day.
The hemodynamic, pharmacokinetic and hormonal pro-
tocols of the late study were identical tn those of the early
study . Vasodilators, digoxin and diuretic drugs were with-
held for at least 18 hours before restudy. MOL 17,043 was
last given between 12 and 24 hours before hemodynamic
restudy.
Patients were examined monthly for the next 6 months
and bimonthly thereafter and as needed. All cardiovascular
drugs could be adjusted according to the clinical status of
the patient. Follow-up data are complete up to May I, 1984.
Statistical analysis. Data are presented as mean
values ± SO unless otherwise specified. Baseline herno-
dynamic measurements were compared with those at each
time period after drug administration using a mixed model
single factor repeated measures analysis of variance (12).
Baseline hormone levels after drug administration were
compared using the Student's t test.
Table 2 . Early a nd Late Hemodyn amic Response to O ral MDL \7 ,04 3 in 6 Pat ie nt s
CI AY0 1 HR SYI RA PA PAW MAP PAR SYR LY SWI
Case (liters /min per m1) (vol % ) (beats /min) (rnl/beats per m2 ) (mm Hg ) (mm Hg) (rnm Hg) (rnm Hg) (dy nes-s-cm ' ) (dynes-s-cm ') (g-rn pe r rrr' )
EB 2.5 7 .2 115 2\ 2 41 15 8 1 435 1.292 19
ER 3. 1 5.7 ios 29 0 24 7 61 138 803 23
LB 2. 1 8 .0 132 16 1I 59 4 1 1I2 349 I A1I7 9
LR 2.9 5 .9 115 25 3 46 20 68 195 906 17
2
EB 2.0 7.4 90 22 7 30 20 68 201 \, 166 15
ER 2.6 5.4 104 27 0 14 5 56 90 1199 2 \
LB 2.4 7 .1 95 25 6 33 22 76 178 \, 135 19
LR 2.6 6 .3 102 27 0 20 9 56 154 1I69 \9
3
EB 1.4 8.0 93 15 12 30 17 73 483 2. 250 12
ER 2.3 5 .0 100 24 6 2ll 15 60 199 1.199 16
LB i. s 6.2 106 17 16 32 23 63 253 I AI7 9
LR 2.2 4 .7 108 22 6 27 18 55 1511 1,167 II
4
EB 1.7 8.6 79 22 7 41 32 ll6 293 1,1l01 18
ER 2.6 6 .0 96 30 ··· 1 17 6 70 153 1.117 30
LB 2.0 8 .1 96 21 3 31 25 90 III 1.776 19
LR 3 .2 5.5 102 34 0 II 7 56 50 931 30
5
EB 2.4 9 .2 107 22 16 53 35 97 306 1.424 \9
ER 3.0 6 .4 116 29 9 40 24 87 2 14 1.040 24
LB 2.2 9 .3 lOll 20 II 45 26 92 343 1.563 18
LR 2.6 6.8 112 25 3 29 15 83 185 1.143 22
6
EB 2.9 5 .5 67 44 4 15 10 1I7 164 1.358 48
ER 3.6 4 .4 90 43 2 9 I 70 108 955 48
LB 3.0 4. 7 72 41 7 23 14 97 138 1.374 46
LR 3.7 3.7 88 43 0 II 3 79 73 999 54
Mean
EB 2. 1 ± 0 .5 7.6 ± 1.3 92 ± 18 25 ± 10 8 ± 5 35 ± 13 22 :!: 10 82 :t 10 314 :!: 126 1.549 :!: 405 22 :!: 13
ER 2.9 ± 0 .5** 5 .5 ± 0 .7** 102 ± 9* 30 :!: 6* 3 ± 4 ** 22 ± II ** 10 :!: 8** 67 ± 11** IS O :!: 19*' 1.002 ± 146** 27 ~ 11*
LB 2.2 ± 0.4 7 .3 :!: 1.6 10 2 :t 20t 23 :t 9 8 ± 4 30 :!: II 25 :!: 9 X3 ± 12 229 .:!: IOJ 1.45 9 ± 2 13 20 ± 14
LR 2.9 :!: 0 .5** 5.5 :!: I. I " 105 :t 10 29 ::!: 8 ' 2 :!: 2** 24 :!.- 13" 12 ::!: 7" 66 :!: 13** 139 :!: 60** 1.00 2 :!: 126** 25 :!: 15'
The table report s base line to peak hemodynamic change tor each variabl e noted . EB = ea rly basel ine: ER = ea rly response : LB = late baselin e :
LR = late res po nse: PI = patient number: SYI = stroke volume index: other abbreviations as in Table I. tp < 0 .05 early vers us late baseline; *p <
0 .05 : **p < 0 .01 basel ine versus peak respon se (either early or late study) .
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Table 3. Early Hormonal Response to Oral MDL 17,043
in 20 Patients
*0.1 < P > 0.05. AVP = arginine vasopressin; NE = norepinephrine;
PRA = plasma renin activity. Normal range: NE = 104 to 548 pg/rnl;
PRA = l.l to 5.4 ng/ml per h; AVP = 0.4 to 1.8 pg/ml.
3.4 ± 3.6 [pg/ml]). Late hormone responses were similar
to early responses with a small nonsignificant decrease in
plasma norepinephrine levels at 1 and 4 hours (1 hour 593
± 411 pg/ml; 4 hours 622 ± 478), a moderate increase in
plasma renin activity (I hour 15.3 ± 15.9 ng/ml per h; 4
hours 22.3 ± 23.0) and no directional change in plasma
arginine vasopressin (I hour 1.70 ± 0.6 pg/ml; 4 hours 2.4
± 1.2).
Pharmacokinetic response. In the early study, the plasma
MDL 17,043 concentration (540 ± 234 ng/ml) peaked at
1.6 ± 1.2 hours after administration, whereas the plasma
level of MDL 19,438 (1,818 ± 651 ng/ml) peaked at 2.5
± 1.6 hours after administration. The elimination half-life
was estimated to be 20.0 ± 5.8 hours (range 7.5 to 54.6)
for MDL 17,043 and 25.6 ± 25.0 hours (range 3.4 to 56.5)
for MDL 19,438. No significant differences were found in
MDL 17,043 or MDL 19,438 blood levels between patients
receiving the 3 and 6 mg/kg doses at any time period.
At baseline of the late study (time from last MDL 17,043
dose 23.8 ± 9.1 hours), significant plasma levels of MDL
17,043 (169 ± 152 ng/ml, range 0 to 352) and MDL 19,438
(1,555 ± 2,000 ng/ml, range 0 to 5,415) were present. In
the late study, the values for time to peak plasma level of
MDL 17,043 (2.7 ± 3.2 hours) and MDL 19,438 (4.7 ±
2.7) were similar to those of the early study. The elimination
half-life during long-term use tended to be less but was not
significantly different from that of the early study for both
MDL 17,043 (10.2 ± 3.5 hours, range 4.9 to 13.5) and
MDL 19,438 (13.1 ± 3.1 hours, range 6.2 to 15.3), al-
though large interindividual variation was noted in both the
early and late values.
Clinical response. The median follow-up period was 39
days (range 3 to 260). There was initial symptomatic im-
provement in 18 patients (90%). At 4 weeks, 10 patients
(50%) still showed improvement. Diuretic drugs were main-
tained at prestudy levels in five patients, increased in three
and decreased in two. Of the responders on captopril
prestudy, two had the agent discontinued and one continued
at the prestudy dose. Three of six patients receiving a nitrate
preparation before the study had the drug discontinued at 4
weeks; the other three continued the nitrate maintained at
prestudy levels. Long-term (>3 months) improvement oc-
curred in 5 patients (25%). Diuretic drug dosage was de-
PRA (ng/ml per h)
NE (pg/rnl)
AVP (pg/ml)
Baseline
7.7 ± 9.4
869 ± 500
4.4 ± 4.4
I Hour After
MOL 17,043
8.2 ± 7.4
794 ± 419
5.8 ± 7.1
4 Hours After
MOL 17,043
13.6 ± 12.8*
748 ± 372*
3.8 ± 4.2
creased over baseline in two patients, was unchanged in
two and increased in one. One of the long-term responders
who had been receiving captopril before the study had cap-
topril withdrawal continued at 3 months; the other long-
term responder remained on the prestudy captopril dose.
Two of three patients were withdrawn from isosorbide din-
itrate and the other patient was maintained on the prestudy
dose. Prazosin was discontinued by 3 months in one patient
who had also been withdrawn from isosorbide dinitrate by
4 weeks.
Adverse effects occurred in 16 (75%) of 20 patients.
Gastrointestinal symptoms were most frequent, with diar-
rhea or frequent (3 to 6/day) episodes of loose stools, nau-
sea, vomiting or abdominal cramping in 13 patients (65%).
Headache developed in two patients. A single patient de-
veloped reversible agranulocytosis.
Side effects required cessation ofdrug administration in
two patients (agranulocytosis in one and nausea and diar-
rhea in one). One patient was withdrawn from the study
because he underwent heart transplantation. One patient was
withdrawn by the referring physician because of the devel-
opment of an asymptomatic sinus tachycardia (87 beats/min
before treatment to 110 beats/min after the start of MDL
17,043 therapy), although the investigators believed that the
remainder of the hemodynamic response warranted a ther-
apeutic trial. One patient was withdrawn by the investigators
because of poor compliance. Of the remaining 14 patients,
13 (93%) have died (median time of death after MDL 17,043
institution 39 days, range 3 to 235). Nine (69%) of these
deaths were sudden, one in the setting of digitalis toxicity;
seven of these nine patients were receiving an antiarrhythmic
drug at the time of death. Three sudden deaths were wit-
nessed by medical personnel. In all medically witnessed
sudden deaths, ventricular tachycardia and fibrillation were
noted.
With long-term use, there were no changes in any lab-
oratory variables except in the single patient in whom agran-
ulocytosis developed.
Discussion
Hemodynamic response. Oral MDL 17,043 improved
cardiac performance to a level similar to that reported by
us with the intravenous form of the agent (4). Both the
intravenous and oral preparations produced significant de-
creases in right atrial and pulmonary artery wedge pressures
and an increase in cardiac output. There was a small but
significant decrease in mean systemic and pulmonary artery
pressures and a modest increase in heart rate. Both forms
of administration produce a sustained hemodynamic effect.
In the present study, all hemodynamic variables were still
significantly altered 8 hours after drug ingestion. There also
appear to be significant differences in response to the two
dosing forms. In the doses employed in the intravenous and
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oral studies, the peak decreases in mean right atrial, pul-
monary artery, pulmonary artery wedge and systemic ar-
terial pressures were comparable. In contrast, peak cardiac
output averaged 76% improvement after intravenous admin-
istration, but only 28% in the present oral study.
In the intravenous study, cardiac output tended to peak
with an MOL 17,043 dose of 5 to 6 mg/kg. In the present
study, 3 mg/kg produced as great an improvement in cardiac
output as did 6 mg/kg. Although the reason for the differ-
ences in cardiac output can only be speculated on, it is of
interest that the plasma drug levels of MOL 17,043 and
MOL 19,438 after oral administration at peak cardiac output
for 3 and 6 mg/kg were similar. These data suggest a lim-
itation of oral absorption of MOL 17,043 at a dose of 3
mg/kg or less. It may be, therefore, that at similar doses
the plasma drug concentrations of both MOL 17,043 and
MOL 19,438 are significantly higher with intravenous than
with oral administration, accounting for the differences in
cardiac output. Because preload and afterload changes were
similar with the oral and intravenous preparations, it is sug-
gested that the greater increase in cardiac output with the
intravenous form may be related to an inotropic response
apparent at higher MOL 17,043 plasma levels.
Hemodynamic responsiveness was maintained in the six
patients studied at 4 weeks. This time period was chosen
as a compromise between a longer restudy time and the
expected patient attrition from the underlying condition. In
studies utilizing beta-receptor agonists and arterial vasodi-
lators, loss of hemodynamic effects including short-term
tachyphylaxis and long-term attenuation or complete loss
of response have been reported from 1 day to 4 weeks after
drug institution (13-16). Thus, we believe that 4 weeks
represent a reasonable, practical compromise to observe a
chronic effect. It should be emphasized that of the six pa-
tients studied, all felt subjectively improved. Thus, it is
concluded that in patients who have clinical improvement,
hemodynamic responsiveness is maintained. It remains to
be determined whether patients whose clinical condition
worsens or does not improve also maintain hemodynamic
responsivity.
Hormonal response. This study emphasizes the heter-
ogeneity of hormonal responses to heart failure. In only
35% of patients were plasma norepinephrine, renin activity
and arginine vasopressinlevels all elevated at baseline. Plasma
vasopressin was the most frequently elevated; all three hor-
mones showed wide plasma level variation. Plasma renin
activity tended to increase (0.1 < P > 0.05) after admin-
istration of oral MOL 17,043 (a response similar to that
seen with the intravenous form of the agent [17]). The
stimulus for this increase may only be speculated on from
this study. It may be that the small but consistent decrease
in mean arterial pressure decreased renal perfusion pressure,
thus stimulating renin release. The improvement in cardiac
performance did not translate to a suppression of either
plasma norepinephrine or arginine vasopressin levels, which
may beexpected on the basis of cardiovascularfactors known
to stimulate or depress secretion of these hormones (18).
At the 4 week restudy, hormone levels were similar to those
determined at the early study. The long-term hormonal re-
sponse in patients who have improved clinically on therapy
has not been completely characterized (19,20). These data
suggest that, at least with oral MOL 17,043, subjective
improvement is not associated with suppression of the hor-
mone systems studied.
Pharmacokinetic response. Pharmacokinetic data re-
veal that MOL 17,043 is relatively rapidly absorbed with a
long elimination half-life in patients with heart failure. It
undergoesa reversibleconversion in the liver to MOL 19,438,
a metabolite with approximately 20% of the hemodynamic
activity, at least in dogs, as MOL 17,043 (4). Our study
indicates that a plateau in plasma levels occurs after oral
administration such that the plasma levels after a single 6
mg/kg dose were not significantly higher than those after a
3 mg/kg dose. A concomitant plateau in hemodynamic mea-
surements was observed, which may be related to the com-
parable plasma drug levels. A limitation in absorption as
seen with certain other drugs, including tetracycline, phe-
nytoin, phenylbutazone and chlorthiazide, among others (21),
may be the cause of the plasma level plateau. Although the
long elimination half-life might recommend an infrequent
dosing interval, for example, every 12 to 24 hours, the
plasma drug level plateau after oral administration suggests
that a rather more frequent dosing schedule would allow for
higher drug levels and possibly a greater hemodynamic ef-
fect, particularly in cardiac output.
The late pharmacokinetic response resembled the early
response. Thus, pharmacokinetic modification by hepatic
enzyme induction or other mechanisms probably does not
occur.
Clinical response. Because of the protocol employed in
the clinical follow-up study, caution should be used in in-
terpreting the clinical efficacy of this agent. The lack of a
blinding procedure and a placebo control group prevents
any conclusion as to how much of the clinical response was
placebo effect. Vasodilators were reinstituted in many pa-
tients and diuretic drugs continued in all, which may have
accounted for at least part of the clinical response. However,
patients receiving vasodilators were referred for MOL 17,043
because of a response that was considered to be unsatisfac-
tory by the referring physician, and in long-term responders
vasodilator dosage was either maintained or reduced com-
pared with prestudy levels. Many of the patients receiving
MOL 17,043 were hospitalized for severe heart failure at
the time of drug study. Although the drug was given at a
time of "clinical stability," we consider that at least some
of the immediate subjective improvement was due to a com-
bination of supportive care and increased attention from the
medical and nursing personnel involved in this study, as
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well as a placebo effect. The clinical response should be
interpreted with these caveats in mind.
Initial subjective improvement with MDL 17,043 in 90%
of the patients is encouraging. However, only 25% were
long-term (>3 month) responders. It is difficult to deter-
mine, in the absence of a control group, whether this percent
is, in fact, acceptable, particularly in view of the extreme
severity of these patients' status. Side effects were frequent
and required drug termination in 10%.
The death rate of 93% (13 of 14 patients on long-term
therapy) is higher than that in recent prospective studies of
patients with "refractory" heart failure (22,23), most of
whom were taking vasodilators, digoxin and diuretic drugs.
Franciosa et al. (22) reported an overall mortality rate of
34% at I year; it was higher in patients with coronary artery
disease (46%) than in those with idiopathic dilated cardio-
myopathy (23%). Wilson et al. (23) demonstrated a I year
mortality rate of 48% with a similar death rate in patients
with ischemia and dilated cardiomyopathy. Similarly, the
percent (69%) of sudden deaths in our series is higher than
in other studies (22,23). The percent of sudden death in the
series of Franciosa et al. (22), using a definition of "sud-
den" comparable with that in our series, was 45%. In the
study by Wilson et al. (23), death occurred suddenly in 43%
of cardiac deaths. Our study group and those reported by
others may not, however, be comparable. Although the two
studies cited utilized patients with "refractory" heart fail-
ure, the patients in our study may have been even more
severely ill. The ejection fraction of the patients in the series
of Wilson et al. was somewhat higher (27 ± 10%) than in
our study (16 ± 5%). Franciosa et al. demonstrated hemo-
dynamic differences in survivors versus nonsurvivors. The
hemodynamic profile of patients in our series more closely
resembles that of the nonsurvivors (except that it is slightly
worse for most variables) than that of the survivors. Thus,
the higher mortality in this series may actually reflect the
extreme severity of the patients' cardiac status. Further-
more, the high percent of patients with sudden death may
reflect a decrease in deaths from terminal heart failure with-
out significant overall improvement in survival, thus pro-
ducing a higher relative incidence of sudden deaths. On the
other hand, if the survival rate actually decreases, this find-
ing may represent a direct detrimental effect of MDL 17,043
on survival. A randomized, controlled trial using patients
who have a reasonable expectation of at least I year's sur-
vival (functional classes II and III) will be required to resolve
whether MDL 17,043 is efficacious and safe.
We gratefully acknowledge the secretarial assistance of Darlene Thiel and
Elsie Ebennan, the technical assistance of Albert Durica, Bettye P. Bell,
Michael Fredrick, Elizabeth Mackie and Darina Sipula and the nursing
assistance of Donna Mulkern and Sally Thomas.
References
1. Dage RC, Roebel LE, Hsieh CP, Wiener DL, Woodward IK. Car-
diovascular properties of new cardiotonic agent MOL 17,043 0,3-
dihydro-4-methyl-5-[4-(methylthio)-bezoyl]-2H-imidazol-2-one). J
Cardiovasc Pharm 1982;4:500-8.
2. Farah AE, Alousi AA. New cardiotonic agents: a search for digitalis
substitute. Life Sci 1978;22:1139-48.
3. Diederen W, Weisenberger H. Studies on the mechanism of the pos-
itive-inotropic action of AR-L 115 BS, a new inotropic drug. Arzneim
Forsch Drug Res 1981;31:177-82.
4. Uretsky BF, Generalovich T, Reddy PS, Spangenberg RB, Follansbee
WP. The acute hemodynamic effects of a new agent, MOL 17,043,
in the treatment of congestive heart failure. Circulation 1983;67:823-8.
5. Roebel LE, Dage RC, Cheng HC, Woodward IK. Charcterization of
the cardiovascular activities of a new cardiotonic agent MOL 17,043(1,3-
dihydro-4-methyl-5-[4-(methylthio)-benzoyl]-2H-imidazol-2-one). J
Cardiovasc Pharm 1982;4:721-9.
6. Kariya T, Wille U, Dage RC. Biochemical studies on the mechanism
of cardiotonic activity of MOL 17,043. J Cardiovasc Phann
1982;4:509-14.
7. Uretsky BF, Generalovich T, Reddy PS, et al. Acute hemodynamic
effect of oral MOL 17,043 in severe congestive heart failure. Am J
Cardiol 1984;54:357-62.
8. Davis GC, Kissinger P, Shuoup R. Strategies for determination of
serum or plasma norepinephrine by reverse phase liquid chromatog-
raphy. Anal Chern 1981;53:156-9.
9. Haber E, Koerner J, Page LB, Kliman BM, Purvode A. Application
of a radioimmunoassay for angiotensin I to the physiologic measure-
ment of plasma renin activity in normal human subjects. J Clin En-
docrinol Metab 1969;29:1349-55.
10. Seif SM, Robinson AG, Zenser TV, Davis BB, Huellmantel AE,
Haluszczak C. Neurohypophyseal peptides in hypothyroid rats: plasma
levels and kidney response. Metabolism 1979;28: 137-43.
II. Chan KY, Ohlweiler OF, Lang JF, Okerholm RA. Simultaneous anal-
ysis of a new cardiotonic agent, MOL 17,043 and its major sulfoxide
metabolite in plasma by high performance liquid chromatography. J
Chromatogr 1984;306:249-56.
12. Winer BI. Statistical Principles in Experimental Design. 2nd ed. New
York: McGraw-Hill, 1971:276.
13. Colucci WS, Alexander W, Williams GH, et al. Decreased lymphocyte
beta-adrenergic-receptor density in patients with heart failure and tol-
erance to the beta-adrenergic agonist pirbuterol. N Engl J Med
1981;305: 185-90.
14. Tarazi RC, Fouad PM, Ceimo JK, Bravo EL. Renin, aldosterone and
cardiac decompensation: studies with an oral converting enzyme in-
hibitor in heart failure. Am I Cardiol 1979;44:1013-8.
15. Packer M, Meller I, Gorlin R, Herman MV. Hemodynamic and clin-
ical tachyphylaxis to prazosin-rnediated afterload reduction in severe
chronic congestive heart failure. Circulation 1979;59:531-9.
16. Arnold SB, Williams RL, Ports TA, et al. Attenuation of prazosin
effect on cardiac output in chronic heart failure. Ann Intern Med
1979;91:345-9.
17. Uretsky BF, Generalovich T, Reddy PS. The relationship of cate-
cholamine and plasma renin activity levels to improved hemodynamics
with MOL 17,043 in patients with congestive heart failure (abstr). J
Am Coil Cardiol 1983;1:676.
18. Cowley AW Jr. Vasopressin and cardiovascular regulation. Cardio-
vascular physiology IV. Int Rev Physiol 1982;26: 189-242.
19. Stein L. Plasma norepinephrine remains high during long-term vaso-
dilator therapy of congestive heart failure regardless of outcome (abstr).
J Am Coil Cardiol 1984;3:560.
20. Bayliss J, Norell M, Canepa-Anson R, Reid C, Poole-Wilson P, Sutten
G. Importance of neuroendocrine mechanisms during vasodilator ther-
JACC Vol. 5. No.6
June 1985:1414-21
URETSKY ET AL.
MDL 17.043 THERAPY IN HEART FAILURE
1421
apy of heart failure: double-blind comparison of captopril and prazosin
(abstr). Circulation 1983;68(suppllIl):1I1-1 29.
21. Wood JH. Thakker KM. Michaelis-Menten absorption kinetics in drugs;
examples and implications. Eur J Clin Pharmacol 1982;23:183- 8.
22. Franciosa JA. Wilen M. Ziesche JS. Cohn IN . Survival in men with
severe chronic left ventricular failure due to either coronary heart
disease or idiopathic dilated cardiomyopathy. Am J Cardiol
1983;51:831- 6 .
23. Wilson JR, Schwartz JS . Sutton MSJ, et al. Prognosis in severe heart
failure: relation to hemodynamic measurements and ventricular ectopic
activity. J Am Coil Cardiol 1983;2:403-10.
